Cardiovascular-Kidney-Metabolic (CKM) Syndrome , as defined by the AHA, is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors (such as obesity, insulin resistance, dyslipidemia, and hypertension), chronic kidney disease (CKD), and the cardiovascular system, leading to multiorgan dysfunction and a high rate of adverse cardiovascular outcomes [145]
Semaglutide, a GLP-1 receptor agonist originally designed for type 2 diabetes, has demonstrated significant effects on lipid metabolism beyond weight reduction
Currently available over-the-counter GLP-1 patches have not been shown to deliver GLP-1 or produce the same metabolic effects as prescription therapies
Many providers address this by starting patients on 10mg/ml vials and transitioning to 20mg/ml vials once they reach the 10mg dose level
Accessed 5 Nov 2025
How the Weight Loss Program at Optimize Medical Works At Optimize Medical, we offer a structured weight loss program designed to support you at every step of your journey
